Stock listing
BOATS:IBIO iBio, Inc. Stock
US listing (BOATS) of iBio, Inc. · home listing NASDAQ:IBIO
Follow iBio, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:IBIO
$0.80 USD -0.05 (-5.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:IBIO
- Day range
- $0.763 – $0.827 USDNov 20, 2026
- Volume
- 3.36M sharesNov 20, 2026
- Market cap
- $51.45M USDAt the close on Nov 20, 2026 · price × 64.31M shares outstanding
- 52-week range
- $0.675 – $3.82 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $726,570 USDMedian day 436,011 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IBIO · Home | $0.80 USD | -0.048 (-5.7%) | 3,363,632 | $0.796 | $0.827 | $0.763 | $0.848 | Close on Nov 20, 2026 |
| Frankfurt:0JV0 | €0.714 EUR | 0.000 (0.0%) | — | €0.677 | €0.714 | €0.677 | €0.714 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IBIO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.80 | -0.048 | -5.7% | $0.796 | $0.827 | $0.763 | 3,363,632 | |
| $0.848 | +0.10 | +13.4% | $0.75 | $0.868 | $0.75 | 842,564 | |
| $0.748 | +0.041 | +5.9% | $0.705 | $0.762 | $0.70 | 520,871 | |
| $0.707 | -0.025 | -3.4% | $0.74 | $0.775 | $0.675 | 586,955 | |
| $0.732 | -0.03 | -4.0% | $0.786 | $0.80 | $0.703 | 451,700 | |
| $0.762 | -0.062 | -7.5% | $0.83 | $0.832 | $0.76 | 299,174 | |
| $0.824 | +0.044 | +5.7% | $0.792 | $0.833 | $0.77 | 361,180 | |
| $0.78 | -0.015 | -1.9% | $0.795 | $0.80 | $0.77 | 221,667 | |
| $0.795 | +0.056 | +7.6% | $0.76 | $0.828 | $0.75 | 668,636 | |
| $0.739 | +0.009 | +1.2% | $0.75 | $0.767 | $0.713 | 289,400 | |
| $0.73 | -0.07 | -8.7% | $0.775 | $0.79 | $0.701 | 694,151 | |
| $0.80 | -0.023 | -2.9% | $0.841 | $0.85 | $0.80 | 277,394 | |
| $0.824 | +0.024 | +3.0% | $0.80 | $0.836 | $0.79 | 397,317 | |
| $0.80 | +0.031 | +4.1% | $0.80 | $0.80 | $0.75 | 307,069 | |
| $0.769 | -0.045 | -5.5% | $0.81 | $0.811 | $0.74 | 213,524 | |
| $0.814 | +0.009 | +1.2% | $0.819 | $0.83 | $0.777 | 247,599 | |
| $0.804 | +0.037 | +4.9% | $0.77 | $0.808 | $0.74 | 280,700 | |
| $0.767 | +0.06 | +8.5% | $0.707 | $0.774 | $0.69 | 474,565 | |
| $0.707 | -0.013 | -1.8% | $0.73 | $0.73 | $0.686 | 508,951 | |
| $0.72 | -0.06 | -7.7% | $0.77 | $0.78 | $0.71 | 653,900 | |
| $0.78 | -0.06 | -7.1% | $0.84 | $0.85 | $0.75 | 654,800 | |
| $0.84 | +0.02 | +2.4% | $0.84 | $0.88 | $0.84 | 517,900 | |
| $0.82 | +0.06 | +7.9% | $0.76 | $0.89 | $0.76 | 2,212,300 | |
| $0.76 | -0.01 | -1.3% | $0.76 | $0.78 | $0.75 | 354,100 | |
| $0.77 | -0.01 | -1.3% | $0.78 | $0.80 | $0.76 | 310,000 | |
| $0.78 | 0.00 | 0.0% | $0.75 | $0.82 | $0.75 | 348,500 | |
| $0.78 | 0.00 | 0.0% | $0.78 | $0.81 | $0.73 | 1,433,800 | |
| $0.78 | -0.12 | -13.3% | $0.90 | $0.90 | $0.77 | 1,343,700 | |
| $0.90 | +0.03 | +3.4% | $0.89 | $0.95 | $0.88 | 452,100 | |
| $0.87 | -0.05 | -5.4% | $0.92 | $0.97 | $0.85 | 1,642,000 | |
| $0.92 | -0.09 | -8.9% | $1.00 | $1.00 | $0.90 | 684,800 | |
| $1.01 | -0.04 | -3.8% | $1.05 | $1.06 | $0.97 | 2,707,900 | |
| $1.05 | -0.07 | -6.3% | $1.12 | $1.15 | $1.02 | 1,207,600 | |
| $1.12 | -0.01 | -0.9% | $1.14 | $1.18 | $1.08 | 1,126,100 | |
| $1.13 | +0.02 | +1.8% | $1.12 | $1.15 | $1.07 | 531,200 | |
| $1.11 | -0.07 | -5.9% | $1.18 | $1.21 | $1.10 | 337,900 | |
| $1.18 | +0.01 | +0.9% | $1.19 | $1.22 | $1.17 | 227,900 | |
| $1.17 | 0.00 | 0.0% | $1.20 | $1.20 | $1.16 | 234,300 | |
| $1.17 | -0.02 | -1.7% | $1.19 | $1.19 | $1.15 | 295,600 | |
| $1.19 | -0.01 | -0.8% | $1.23 | $1.24 | $1.15 | 617,600 | |
| $1.20 | -0.05 | -4.0% | $1.25 | $1.25 | $1.19 | 376,300 | |
| $1.25 | -0.08 | -6.0% | $1.32 | $1.35 | $1.24 | 363,700 | |
| $1.33 | +0.07 | +5.6% | $1.28 | $1.37 | $1.24 | 2,092,200 | |
| $1.26 | -0.02 | -1.6% | $1.29 | $1.31 | $1.26 | 385,500 | |
| $1.28 | +0.03 | +2.4% | $1.26 | $1.30 | $1.24 | 440,600 | |
| $1.25 | +0.07 | +5.9% | $1.25 | $1.31 | $1.21 | 2,090,500 | |
| $1.18 | -0.01 | -0.8% | $1.19 | $1.20 | $1.17 | 406,900 | |
| $1.19 | -0.01 | -0.8% | $1.20 | $1.22 | $1.17 | 375,800 | |
| $1.20 | -0.01 | -0.8% | $1.23 | $1.23 | $1.20 | 324,000 | |
| $1.21 | -0.02 | -1.6% | $1.24 | $1.24 | $1.20 | 184,800 | |
| $1.23 | -0.03 | -2.4% | $1.26 | $1.26 | $1.22 | 308,900 | |
| $1.26 | -0.04 | -3.1% | $1.30 | $1.30 | $1.25 | 404,600 | |
| $1.30 | -0.01 | -0.8% | $1.31 | $1.32 | $1.28 | 190,900 | |
| $1.31 | +0.01 | +0.8% | $1.29 | $1.33 | $1.28 | 265,400 | |
| $1.30 | -0.01 | -0.8% | $1.32 | $1.35 | $1.29 | 353,500 | |
| $1.31 | +0.05 | +4.0% | $1.26 | $1.34 | $1.26 | 310,700 | |
| $1.26 | -0.01 | -0.8% | $1.27 | $1.30 | $1.21 | 2,232,800 | |
| $1.27 | -0.09 | -6.6% | $1.37 | $1.37 | $1.25 | 875,800 | |
| $1.36 | -0.04 | -2.9% | $1.42 | $1.42 | $1.34 | 513,500 | |
| $1.40 | -0.03 | -2.1% | $1.43 | $1.46 | $1.40 | 374,500 | |
| $1.43 | -0.04 | -2.7% | $1.47 | $1.47 | $1.43 | 259,200 | |
| $1.47 | +0.05 | +3.5% | $1.41 | $1.48 | $1.41 | 436,011 | |
| $1.42 | -0.01 | -0.7% | $1.45 | $1.45 | $1.371 | 514,909 | |
| $1.43 | -0.04 | -2.7% | $1.46 | $1.50 | $1.42 | 754,700 | |
| $1.47 | -0.02 | -1.3% | $1.47 | $1.50 | $1.44 | 1,977,100 |
Splits
3 splits since 2018 · NASDAQ:IBIO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation | |
| 1-for-25 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- BOATS:IBIO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 29 slides
Latest news
iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences
Nov 16, 2026
Closed $0.748 (+5.9%) on Nov 17, 2026
iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update
Nov 10, 2026
Closed $0.824 (+5.7%) on Nov 11, 2026
iBio to Participate in Upcoming Investor Conferences
Nov 2, 2026
Closed $0.824 (+3.0%) on Nov 3, 2026
iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
Oct 13, 2026
Closed $0.78 (-13.3%) on Oct 13, 2026
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)
Sep 16, 2026
Closed $1.18 (-0.8%) on Sep 16, 2026
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
Sep 1, 2026
Closed $1.31 (+4.0%) on Sep 2, 2026
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Aug 28, 2026
Closed $1.36 (-2.9%) on Aug 28, 2026
IntraBio’s Pivotal Phase III Trial in CACNA1A-Related Disorders Is Enrolling and Is Expected to Be Over-Enrolled and Complete Recruitment in October
Aug 19, 2026
Closed $1.49 (+2.8%) on Aug 19, 2026
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
Aug 4, 2026
Closed $1.46 (+2.8%) on Aug 4, 2026
IntraBio Announces Submission of Variation Application to the European Medicines Agency for AQNEURSA® for Ataxia-Telangiectasia
Jun 5, 2026
Closed $1.82 (-5.7%) on Jun 5, 2026
iBio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 21 in the last 12 months · 118 in all · newest Nov 16, 2026 · oldest 2019
- Decks
- 21 decks · latest November 2026
Where iBio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IBIO · Home listing | NASDAQ | United States | USD |
| Tradegate:0JV0 | Tradegate | Germany | EUR |
| gettex:0JV0 | gettex | Germany | EUR |
| BOATS:IBIO · This page | BOATS | United States | USD |
| Munich:0JV0 | Munich | Germany | EUR |
| Frankfurt:0JV0 | Frankfurt | Germany | EUR |
| Stuttgart:0JV0 | Stuttgart | Germany | EUR |
Valuation
EV/sales −21.5× against a median of 8.6×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$23.13M USD
- P/E
- Loss
- EV/sales
- −21.5×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- 126.9%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 2.01
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| iBio, Inc. · NASDAQ:IBIO | US$51.45M | −US$23.13M | n/a | −21.5× | n/a | 0.7× | n/a | 0.0× | 2.01 |
| Boundless Bio, Inc. · NASDAQ:BOLD | US$53.61M | −US$9.28M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.65 |
| Xilio Therapeutics, Inc. · NASDAQ:XLO | US$53.40M | −US$62.82M | n/a | −1.1× | n/a | 0.8× | −20.9% | 0.1× | 0.76 |
| Impact BioMedical, Inc. · AMEX:IBO | US$53.31M | US$53.29M | 33.0× | 1,402× | n/a | 5.3× | n/a | 0.0× | 0.06 |
| XBiotech Inc. · NASDAQ:XBIT | US$52.74M | −US$52.29M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 0.52 |
| Bonus Biogroup Ltd. · TASE:BONS | US$52.22M | US$54.52M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sirnaomics Ltd. · HKEX:2257 | US$51.13M | US$69.20M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cinclus Pharma Holding AB · OMXSTO:CINPHA | US$51.07M | US$13.13M | n/a | 3.8× | n/a | 2.6× | −765.8% | 0.0× | n/a |
| Aldeyra Therapeutics, Inc. · NASDAQ:ALDX | US$50.70M | US$9.72M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 0.66 |
| Clene Inc. · NASDAQ:CLNN | US$50.69M | US$58.31M | n/a | 245× | n/a | n/a | n/a | n/a | 1.48 |
| Aptamer Sciences, Inc. · KRX:291650 | US$49.50M | US$34.66M | n/a | 8.6× | n/a | 1.6× | −215.8% | 0.0× | n/a |
| Median of the others | US$51.67M | US$23.90M | 33.0× | 8.6× | 1.4× | −215.8% | 0.0× | 0.66 |
Forecasts
8 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 5.69 USD · Analysts' mean
- EPS, year to Jun 2027
- -0.37 · 9 analysts
- Revenue, year to Jun 2027
- 25K · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Martin Brenner | Chief Executive Officer and Chief Scientific Officer |
| Felipe Duran | Chief Financial Officer |
| Marc Banjak | Chief Legal Officer |
| Endocrinologist Molly Carr | Chief Medical Officer |
| Molly Carr | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Chip Clark | Chairman of the Board |
| Alexandra Kropotova | Director |
| António Parada | Director |
| David Arkowitz | Director |
| Elizabeth Stoner | Director |
| Gary Sender | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2027 | Nov 10, 2026 · After close | +5.7% |
| Q4 2026 | Aug 28, 2026 · Before open | −2.9% |
| Q3 2026 | May 13, 2026 | −3.1% |
| Q2 2026 | Feb 10, 2026 · After close | −2.6% |
| Q1 2026 | Nov 12, 2025 | −7.3% |
| Q4 2025 | Sep 5, 2025 · Before open | +3.7% |
| Q3 2025 | May 2, 2025 · Before open | −1.9% |
| Q2 2025 | Feb 10, 2025 · After close | −7.3% |
| Q1 2025 | Nov 12, 2024 · After close | −9.0% |
| Q4 2024 | Sep 25, 2024 · After close | +7.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2024 | May 13, 2024 · After close | +3.3% |
| Q2 2024 | Feb 9, 2024 · After close | +2.5% |
| Q1 2024 | Nov 13, 2023 · After close | −3.5% |
| Q4 2023 | Sep 27, 2023 · After close | 0.0% |
| Q3 2023 | May 15, 2023 · Before open | −6.9% |
| Q2 2023 | Feb 14, 2023 · After close | −3.4% |
| Q1 2023 | Oct 11, 2022 · After close | −1.6% |
| Q4 2022 | Sep 27, 2022 · After close | −34.4% |
| Q3 2022 | May 12, 2022 · After close | −7.4% |
| Q2 2022 | Feb 14, 2022 · After close | −2.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 29 slides | November 2026 |
| Investor Presentation (September 2026) | Investor deck | 29 slides | September 2026 |
| Investor Presentation (March 2026) | Investor deck | 39 slides | Mar 9, 2026 |
| Investor Presentation (August 2025) | Investor deck | 34 slides | Aug 18, 2025 |
| Investor Presentation (June 2025) | Investor deck | 45 slides | Jun 24, 2025 |
| Investor Presentation (April 2025) | Investor deck | 87 slides | Apr 8, 2025 |
| Investor Presentation (January 2025) | Investor deck | 81 slides | Jan 10, 2025 |
| Investor Presentation (October 2024) | Investor deck | 72 slides | Oct 23, 2024 |
| Investor Presentation (June 2024) | Investor deck | 67 slides | Jun 3, 2024 |
| Investor Presentation (January 2024) | Investor deck | 66 slides | Jan 8, 2024 |
All 21 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2023) | Investor deck | 53 slides | Oct 2, 2023 |
| Investor Presentation (July 2023) | Investor deck | 47 slides | Jul 10, 2023 |
| Investor Presentation (April 2023) | Investor deck | 46 slides | Apr 24, 2023 |
| Investor Presentation (November 2022) | Investor deck | 33 slides | Nov 3, 2022 |
| Investor Presentation (October 2022) | Investor deck | 23 slides | Oct 3, 2022 |
| Investor Presentation (May 2022) | Investor deck | 29 slides | May 16, 2022 |
| Investor Presentation (March 2022) | Investor deck | 30 slides | Mar 18, 2022 |
| Investor Presentation (August 2021) | Investor deck | 32 slides | Aug 30, 2021 |
| IPO Roadshow (October 2019) | IPO roadshow | 24 slides | Oct 11, 2019 |
| IPO Roadshow (June 2018) | IPO roadshow | 24 slides | Jun 13, 2018 |
| Noble Financial Sixth Annual Equity Conference ONTRACK 2010 | Conference | 25 slides | Jun 4, 2010 |
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock (or pre-funded warrants in lieu thereof) Announced: about US$26M · US$2.35 a share · Leerink Partners +2 Dealers: Leerink Partners (lead), LifeSci Capital (co-lead), Oppenheimer & Co. (co-lead) Buyers: Frazier Life Sciences Use of proceeds: Advance preclinical cardiometabolic programs incl. IBIO-610, IBIO-600 and bispecifics, other pipeline assets, working capital and general corporate purposes | Jan 9, 2026 |
| Public offering of pre-funded warrants and accompanying Series G warrants Closed: US$50M raised · US$0.699 a share · ½ warrant at US$0.7 · Leerink Partners +3 Dealers: Leerink Partners (lead), LifeSci Capital, Oppenheimer & Co., Brookline Capital Markets Buyers: Balyasny Asset Management; Cormorant Asset Management; Adage Capital Partners LP; Ally Bridge Group; Marshall Wace; Coastlands Capital; SilverArc Capital Management; Vestal Point Capital; Ausangate Capital Use of proceeds: Advance preclinical cardiometabolic programs incl. IBIO-610 and IBIO-600, other pipeline assets, working capital and general corporate purposes | Aug 25, 2025 |
| Warrant exercise of shares of common stock upon exercise of existing warrants Announced: about US$6.2M · US$1.11 a share · Warrants at US$0.86 for 60 months · Chardan Dealers: Chardan Use of proceeds: Working capital and other general corporate purposes | Apr 29, 2025 |
| Private placement of private placement offering Closed: US$650,000 raised Insiders: Private placement with members of its Board of Directors and Officers | Jan 13, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 100.0K | 400.0K | 225.0K | 0 | 1.88M | 2.37M | 1.64M | 2.02M | 444.0K | 394.0K |
| Cost of revenue | 1.03M | 1.25M | 1.11M | 216.0K | 1.46M | 703.0K | 13.0M | 13.0M | ||
| Gross profit | 100.0K | 400.0K | 225.0K | 50.0K | 2.17M | 909.0K | 935.0K | 2.02M | 444.0K | 394.0K |
| Research and development | 19.6M | 8.31M | 5.18M | 10.3M | 9.83M | 9.99M | 3.57M | 5.47M | 3.99M | 4.12M |
| Selling, general and administrative | 10.6M | 10.7M | 11.7M | 19.0M | 21.8M | 21.7M | 11.4M | 12.3M | 10.7M | 10.6M |
| Operating income | -35.1M | -18.6M | -16.6M | -29.3M | -29.7M | -31.1M | -14.0M | -15.8M | -14.2M | -14.3M |
| Depreciation and amortization | 558.0K | 484.0K | 638.0K | 674.0K | 2.27M | 472.0K | 282.0K | 179.0K | 1.37M | 1.33M |
| EBITDA | -34.6M | -18.1M | -16.0M | -28.7M | -27.4M | -30.6M | -13.7M | -15.6M | -12.9M | -12.9M |
| Interest expense | 53.0K | 212.0K | 172.0K | 83.0K | 1.41M | 2.45M | 2.47M | 1.90M | 1.92M | 1.93M |
| Income before tax | -33.0M | -18.4M | -15.4M | -29.3M | -29.5M | -23.2M | -16.4M | -17.6M | -16.1M | -14.5M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -33.0M | -18.4M | -24.9M | -65.0M | -50.3M | -23.2M | -16.4M | -17.6M | -16.1M | -14.5M |
| Earnings per share, basic | -0.32 | -1.75 | -6.50 | -106.19 | -5.78 | -3.00 | -0.61 | -0.94 | -1.54 | -1.64 |
| Earnings per share, diluted | -0.32 | -1.75 | -6.50 | -106.19 | -5.78 | -3.00 | -0.61 | -0.94 | -1.54 | -1.64 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 56.4M | 8.58M | 14.2M | 4.30M | 22.7M | 77.4M | 55.1M | 4.42M | 4.42M | 15.9M |
| Short-term investments | 31.6M | 0 | 0 | 0 | 10.8M | 19.6M | 0 | 0 | 0 | |
| Receivables | 1.10M | 0 | 0 | 0 | 1.00M | 426.0K | 75.0K | 97.0K | 75.0K | 175.0K |
| Inventory | 0 | 0 | 3.90M | 27.0K | 798.0K | 1 | 0 | 26.0K | ||
| Current assets | 92.2M | 9.72M | 15.7M | 26.3M | 45.1M | 104.6M | 61.7M | 4.81M | 16.3M | 8.57M |
| Property, plant and equipment | 3.09M | 3.16M | 3.63M | 4.22M | 1.37M | 8.63M | 3.66M | 24.4M | 25.2M | 25.6M |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 99.1M | 23.2M | 28.7M | 41.2M | 99.4M | 147.0M | 94.2M | 30.6M | 43.1M | 36.0M |
| Accounts payable | 4.42M | 2.19M | 358.0K | 1.85M | 4.26M | 2.25M | 1.76M | 1.00M | 790.0K | 749.0K |
| Current liabilities | 11.7M | 6.11M | 3.84M | 22.1M | 30.4M | 6.64M | 5.24M | 3.46M | 2.04M | 2.01M |
| Long-term debt | 766.0K | 339.0K | 24.9M | 25.1M | ||||||
| Total debt | 2.20M | 3.51M | 4.46M | 17.1M | 25.8M | 32.7M | 32.9M | 24.9M | 25.1M | 25.3M |
| Total liabilities | 13.4M | 8.30M | 7.41M | 25.8M | 35.9M | 38.4M | 37.6M | 28.1M | 26.9M | 27.1M |
| Shareholders' equity | 85.7M | 14.9M | 21.3M | 15.4M | 63.5M | 108.6M | 56.6M | 2.46M | 16.2M | 8.91M |
| Shares outstanding | 55.7M | 19.3M | 8.62M | 1.02M | 8.73M | 8.71M | 140.1M | 20.2M | 16.0M | 8.91M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -23.2M | -15.3M | -18.6M | -30.4M | -37.5M | -30.1M | -13.3M | -14.0M | -13.5M | -13.2M |
| Capital spending | -578.0K | -16.0K | -210.0K | -5.74M | -7.33M | -4.92M | -1.08M | -920.0K | -934.0K | -1.32M |
| Free cash flow | -23.8M | -15.3M | -18.8M | -36.2M | -44.8M | -35.0M | -14.4M | -14.9M | -14.4M | -14.5M |
| Cash from investing | -32.0M | 742.0K | 906.0K | 7.01M | -5.13M | -26.5M | -1.15M | -990.0K | -1.08M | -1.59M |
| Cash from financing | 103.0M | 8.93M | 24.5M | 2.30M | -6.13M | 78.8M | 65.2M | 3.45M | 22.4M | -170.0K |
| Dividends paid | -500.0K | -21.6M | 0 | 0 | ||||||
| Share buybacks | 0 | -7.00K | -39.0K | 0 | -40.8M | -159.0K | -125.0K | 0 | ||
| Change in cash | 47.8M | -5.63M | 6.85M | -21.1M | -48.7M | 22.3M | 50.7M | -11.5M | 7.85M | -14.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 8-K · Current report | Oct 19, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 13, 2026 | Current report | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Sep 4, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Sep 4, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Aug 28, 2026 | Annual report | SEC |
| 8-K · Current report | Aug 28, 2026 | Results | SEC |
| PRE 14A · Preliminary proxy statement | Aug 20, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 4, 2026 | Management or board change | SEC |
| 8-K · Current report | Jul 17, 2026 | Current report | SEC |
| 8-K · Current report | Jul 1, 2026 | Current report | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | May 15, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 8-K · Current report | May 8, 2026 | Management or board change | SEC |
| 424B3 · Prospectus | Apr 29, 2026 | Offer document | SEC |
| 8-K/A · Current report, amended | Apr 17, 2026 | Current report | SEC |
| 8-K · Current report | Apr 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 9, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Mar 9, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Mar 6, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 4, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 4, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 27, 2026 | Material contract | SEC |
| S-3 · Registration statement | Feb 27, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Feb 10, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Feb 10, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Feb 9, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 5, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 5, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jan 30, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 22, 2026 | Big-stake notice | SEC |
| D | Jan 22, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 12, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 19, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 16, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 3, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 21, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Nov 17, 2025 | Current report | SEC |
| 10-Q/A · Quarterly report, amended | Nov 17, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Nov 4, 2025 | Current report | SEC |
| 8-K · Current report | Oct 30, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Oct 6, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Oct 6, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Sep 5, 2025 | Annual report | SEC |
| 8-K · Current report | Sep 5, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 26, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 25, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 21, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Aug 21, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 18, 2025 | Results | SEC |
| 424B5 · Prospectus | Aug 18, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 1, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 30, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jun 24, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 24, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jun 24, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 18, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 18, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 18, 2025 | Current report | SEC |
| S-3 · Registration statement | Jun 13, 2025 | Offer document | SEC |
| D | May 7, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 2, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 2, 2025 | Results | SEC |
| 424B5 · Prospectus | Apr 30, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Apr 30, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Apr 30, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 22, 2025 | Material contract | SEC |
| 8-K · Current report | Apr 8, 2025 | Current report | SEC |
| 8-K · Current report | Apr 7, 2025 | Current report | SEC |
| 25 | Mar 3, 2025 | Other filings | SEC |
| CERT · Exchange's certificate of listing | Mar 3, 2025 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Mar 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 19, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Feb 11, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 11, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Feb 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Feb 10, 2025 | Results | SEC |
| CORRESP · Letter to the SEC | Feb 7, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 6, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jan 31, 2025 | Offer document | SEC |
| S-3 · Registration statement | Jan 31, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Material contract | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 3, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 2, 2025 | Material contract | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 25, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 25, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 8-K · Current report | Oct 23, 2024 | Current report | SEC |
| ARS · Annual report to shareholders | Oct 10, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Oct 10, 2024 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | Sep 24, 2024 | Annual report | SEC |
| 10-K · Annual report | Sep 20, 2024 | Annual report | SEC |
| 8-K · Current report | Sep 20, 2024 | Results | SEC |
| 3 · Initial statement of ownership | Aug 14, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 7, 2024 | Other filings | SEC |
| 424B5 · Prospectus | Aug 6, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 2, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 26, 2024 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Jul 25, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Jul 25, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jul 18, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 9, 2024 | Management or board change | SEC |
| 8-K · Current report | Jul 3, 2024 | Material contract | SEC |
| S-3 · Registration statement | Jul 3, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 5, 2024 | Acquisition or disposal | SEC |
| 8-K · Current report | Jun 3, 2024 | Current report | SEC |
| 8-K · Current report | May 20, 2024 | Material contract | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| 4 · Change in ownership | Apr 26, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Apr 25, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 22, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 22, 2024 | Other filings | SEC |
| S-3 · Registration statement | Apr 16, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 9, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Apr 8, 2024 | Big-stake notice | SEC |
This page holds 200 of 914 filings. Open Filings
Cap table
Built by 6ix from iBio, Inc.’s releases · as of Sep 30, 2026
- Common shares
- 64,307,256
- Fully diluted
- 64,307,256
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 64,307,256 | Sep 30, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.70 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Sep 30, 2026 | 64,307,256 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Evert Schimmelpennink Other companies: Contineum Therapeutics, Inc. (President, LENZ Therapeutics · Since at least Apr 4, 2024); LENZ Therapeutics, Inc. (President, Chief Executive Officer, Secretary and Director · Since at least Mar 21, 2024); Pfenex Inc (See Remarks, Director · Oct 1, 2020 – Oct 1, 2020 · Past) | Director · Since at least Jun 7, 2021 |
| Elizabeth Stoner Other companies: Radius Health, Inc. (Director · Dec 17, 2014 – Dec 17, 2014 · Past); Momenta Pharmaceuticals Inc (Director · Jun 11, 2013 – Oct 1, 2020 · Past) | Director · Since at least May 7, 2026 |
| Alexandra Kropotova Other companies: SAB Biotherapeutics, Inc. (CHIEF MEDICAL OFFICER · Since at least Mar 27, 2025) | Director · Since at least Nov 20, 2025 |
| Chip Clark Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least Apr 17, 2025) | Chairman of the Board · Since at least Nov 5, 2026 |
| Dina Masi Other companies: Integrated BioPharma, Inc. (Chief Financial Officer · Since at least Jun 30, 2008) | Interim CFO · Aug 12, 2008 – Aug 12, 2008 · Past |
| John Delta Other companies: Motorsport Games Inc. (Director · Since at least Oct 4, 2022) | Principal Accounting Officer · Oct 1, 2020 – Oct 1, 2020 · Past |
| Jules A Musing Other companies: TherapeuticsMD, Inc. (Director · May 16, 2013 – Sep 29, 2022 · Past) | Director · Feb 1, 2012 – Jul 24, 2012 · Past |
| William D Clark Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least Apr 17, 2025) | Director · Since at least Nov 21, 2024 |
| António Parada | Director · Since at least Feb 10, 2025 |
| David Arkowitz | Director · Since at least Feb 10, 2025 |
All 21 people
| Person | Seat |
|---|---|
| Endocrinologist Molly Carr | Chief Medical Officer · Since at least Aug 4, 2026 |
| Felipe Duran | Chief Financial Officer · Since at least Nov 2, 2026 |
| Gary Sender | Director · Since at least Nov 5, 2026 |
| Glenn Chang | Director · Feb 20, 2019 – Dec 9, 2021 · Past |
| Hill James T General | Director · Dec 9, 2021 – Dec 9, 2021 · Past |
| Marc Banjak | Chief Legal Officer · Since at least Aug 14, 2024 |
| Martin Brenner | Chief Executive Officer and Chief Scientific Officer · Since at least Nov 2, 2026 |
| Molly Carr | Chief Medical Officer · Since at least Jul 31, 2026 |
| Philip K Russell | Director · Feb 20, 2019 – Apr 1, 2019 · Past |
| Robert Kay | Director · Feb 13, 2009 – Jun 12, 2020 · Past |
| Ryan E Terence | Chief Scientific Officer · Feb 20, 2019 – Feb 20, 2019 · Past |
Log in to ask 6ix AI your own questions about iBio, Inc.